alpha-aminopyridine has been researched along with Squamous Cell Carcinoma of Head and Neck in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arshad, S; Brisson, RJ; Dekker, A; DeSouza, JA; Kochanny, S; Saloura, V; Seiwert, TY; Vokes, EE | 1 |
| Caignet, X; El Baroudi, M; Machiels, JP; Pyr Dit Ruys, S; Roger, PP; Schmitz, S; van Caloen, G; Vertommen, D | 1 |
| Ahn, MJ; Cho, BC; Choi, EC; Choi, JW; Hong, MH; Ju, KY; Jung, DM; Kang, HN; Kim, HR; Kim, HS; Kim, J; Kim, KR; Kim, SH; Kim, TM; Koh, YW; Paik, S; Pyo, KH; Shim, HS; Sun, JM; Yoo, J; Yoon, SO; Yun, MR | 1 |
| Chera, B; Lenze, N; Sheth, S | 1 |
| Cho, BC; Choi, HM; Hong, MH; Joo, HS; Kang, HN; Kim, DH; Kim, HR; Lee, Y; Yoon, SO; Yun, MR | 1 |
| Ailles, L; Bratman, SV; Bruce, JP; Erdmann, N; Goldstein, DP; Hope, AJ; Huang, SH; Hyatt, E; Karamboulas, C; Liu, FF; Meens, J; O'Sullivan, B; Pereira, K; Pugh, TJ; Su, J; Tiedemann, R; Weinreb, I; Xu, W | 1 |
| Huang, CI; Hung, SK; Lin, PM; Su, YC; Tai, TS; Wang, CC; Wu, CF | 1 |
| Bozec, A; Chamorey, E; Ebran, N; Gautier, M; Marcie, S; Milano, G; Penault-Llorca, F; Radosevic-Robin, N; Yahia, HB | 1 |
| Chau, NG; Haddad, RI; Tishler, RB | 1 |
| Amin, AR; Anisuzzaman, AS; Chen, Z; Chen, ZG; Haque, A; Rahman, MA; Shin, DM; Wang, D; Zhang, C | 1 |
1 review(s) available for alpha-aminopyridine and Squamous Cell Carcinoma of Head and Neck
| Article | Year |
|---|---|
An evaluation of buparlisib for the treatment of head and neck squamous cell carcinoma.
Topics: Aminopyridines; Class I Phosphatidylinositol 3-Kinases; Head and Neck Neoplasms; Humans; Maximum Tolerated Dose; Morpholines; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Squamous Cell Carcinoma of Head and Neck | 2021 |
2 trial(s) available for alpha-aminopyridine and Squamous Cell Carcinoma of Head and Neck
| Article | Year |
|---|---|
A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer.
Topics: Aged; Aminopyridines; Antineoplastic Agents, Immunological; Cetuximab; Drug Therapy, Combination; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Morpholines; Neoplasm Recurrence, Local; Pilot Projects; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2019 |
Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Survival; Cetuximab; DNA Copy Number Variations; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Nude; Mice, SCID; Middle Aged; Morpholines; Mutation; Neoplasm Transplantation; Progression-Free Survival; Reproducibility of Results; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome; Up-Regulation; Whole Genome Sequencing | 2020 |
7 other study(ies) available for alpha-aminopyridine and Squamous Cell Carcinoma of Head and Neck
| Article | Year |
|---|---|
Preclinical Activity of Ribociclib in Squamous Cell Carcinoma of the Head and Neck.
Topics: Aminopyridines; Animals; Apoptosis; Biomarkers, Tumor; Cell Cycle; Cell Movement; Cell Proliferation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Epithelial-Mesenchymal Transition; Female; Forkhead Box Protein M1; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Purines; Retinoblastoma Protein; Squamous Cell Carcinoma of Head and Neck; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
Topics: Aminopyridines; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Autocrine Communication; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Female; Head and Neck Neoplasms; Humans; Interleukin-6; MAP Kinase Signaling System; Mice; Mice, Inbred NOD; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Receptors, Interleukin-6; RNA, Small Interfering; Squamous Cell Carcinoma of Head and Neck; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2018 |
Patient-Derived Xenografts for Prognostication and Personalized Treatment for Head and Neck Squamous Cell Carcinoma.
Topics: Aminopyridines; Animals; Base Sequence; Benzimidazoles; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinase Inhibitor p16; Female; Humans; Male; Mice, Inbred NOD; Mice, SCID; Middle Aged; Multivariate Analysis; Mutation; Neoplasm Recurrence, Local; Precision Medicine; Prognosis; Regression Analysis; Risk Factors; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
CDK4/6 Inhibitor LEE011 Is a Potential Radiation-sensitizer in Head and Neck Squamous Cell Carcinoma: An
Topics: Aminopyridines; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Head and Neck Neoplasms; Humans; Mouth Neoplasms; Phosphorylation; Purines; Radiation-Sensitizing Agents; Retinoblastoma Binding Proteins; Squamous Cell Carcinoma of Head and Neck; Ubiquitin-Protein Ligases | 2019 |
Combination of phosphotidylinositol-3-kinase targeting with cetuximab and irradiation: A preclinical study on an orthotopic xenograft model of head and neck cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents, Immunological; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Disease Models, Animal; Female; Head and Neck Neoplasms; Mice; Mice, Nude; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays | 2017 |
Highlights in Head and Neck Cancer.
Topics: Aminopyridines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemoradiotherapy; Clinical Trials as Topic; Enzyme Inhibitors; Head and Neck Neoplasms; Humans; Molecular Targeted Therapy; Morpholines; Nasopharyngeal Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Programmed Cell Death 1 Receptor; Squamous Cell Carcinoma of Head and Neck | 2017 |
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cytoprotection; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Mice; Morpholines; Proto-Oncogene Proteins c-akt; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2017 |